Information Provided By: 
Fly News Breaks for March 21, 2017
SGYP
Mar 21, 2017 | 15:35 EDT
BTIG analyst Timothy Chiang said weakness in Synergy Pharmaceuticals is a buying opportunity. The analyst said investor focus is now on the ramp for Trulance in the US market and he believes management is up to the task of successfully launching Trulance via its hybrid sales model which is expected to target approximately 27,000 high-prescribing physicians. Chiang rates Synergy a Buy with an $11 price target.
News For SGYP From the Last 2 Days
There are no results for your query SGYP
